Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19.


Journal

Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543

Informations de publication

Date de publication:
07 2021
Historique:
received: 19 01 2021
revised: 24 03 2021
accepted: 31 03 2021
pubmed: 23 4 2021
medline: 9 7 2021
entrez: 22 4 2021
Statut: ppublish

Résumé

The potential impact of coronary atherosclerosis, as detected by coronary artery calcium, on clinical outcomes in COVID-19 patients remains unsettled. We aimed to evaluate the prognostic impact of clinical and subclinical coronary artery disease (CAD), as assessed by coronary artery calcium score (CAC), in a large, unselected population of hospitalized COVID-19 patients undergoing non-gated chest computed tomography (CT) for clinical practice. SARS-CoV 2 positive patients from the multicenter (16 Italian hospitals), retrospective observational SCORE COVID-19 (calcium score for COVID-19 Risk Evaluation) registry were stratified in three groups: (a) "clinical CAD" (prior revascularization history), (b) "subclinical CAD" (CAC >0), (c) "No CAD" (CAC = 0). Primary endpoint was in-hospital mortality and the secondary endpoint was a composite of myocardial infarction and cerebrovascular accident (MI/CVA). Amongst 1625 patients (male 67.2%, median age 69 [interquartile range 58-77] years), 31%, 57.8% and 11.1% had no, subclinical and clinical CAD, respectively. Increasing rates of in-hospital mortality (11.3% vs. 27.3% vs. 39.8%, p < 0.001) and MI/CVA events (2.3% vs. 3.8% vs. 11.9%, p < 0.001) were observed for patients with no CAD vs. subclinical CAD vs clinical CAD, respectively. The association with in-hospital mortality was independent of in-study outcome predictors (age, peripheral artery disease, active cancer, hemoglobin, C-reactive protein, LDH, aerated lung volume): subclinical CAD vs. No CAD: adjusted hazard ratio (adj-HR) 2.86 (95% confidence interval [CI] 1.14-7.17, p=0.025); clinical CAD vs. No CAD: adj-HR 3.74 (95% CI 1.21-11.60, p=0.022). Among patients with subclinical CAD, increasing CAC burden was associated with higher rates of in-hospital mortality (20.5% vs. 27.9% vs. 38.7% for patients with CAC score thresholds≤100, 101-400 and > 400, respectively, p < 0.001). The adj-HR per 50 points increase in CAC score 1.007 (95%CI 1.001-1.013, p=0.016). Cardiovascular risk factors were not independent predictors of in-hospital mortality when CAD presence and extent were taken into account. The presence and extent of CAD are associated with in-hospital mortality and MI/CVA among hospitalized patients with COVID-19 disease and they appear to be a better prognostic gauge as compared to a clinical cardiovascular risk assessment.

Sections du résumé

BACKGROUND AND AIMS
The potential impact of coronary atherosclerosis, as detected by coronary artery calcium, on clinical outcomes in COVID-19 patients remains unsettled. We aimed to evaluate the prognostic impact of clinical and subclinical coronary artery disease (CAD), as assessed by coronary artery calcium score (CAC), in a large, unselected population of hospitalized COVID-19 patients undergoing non-gated chest computed tomography (CT) for clinical practice.
METHODS
SARS-CoV 2 positive patients from the multicenter (16 Italian hospitals), retrospective observational SCORE COVID-19 (calcium score for COVID-19 Risk Evaluation) registry were stratified in three groups: (a) "clinical CAD" (prior revascularization history), (b) "subclinical CAD" (CAC >0), (c) "No CAD" (CAC = 0). Primary endpoint was in-hospital mortality and the secondary endpoint was a composite of myocardial infarction and cerebrovascular accident (MI/CVA).
RESULTS
Amongst 1625 patients (male 67.2%, median age 69 [interquartile range 58-77] years), 31%, 57.8% and 11.1% had no, subclinical and clinical CAD, respectively. Increasing rates of in-hospital mortality (11.3% vs. 27.3% vs. 39.8%, p < 0.001) and MI/CVA events (2.3% vs. 3.8% vs. 11.9%, p < 0.001) were observed for patients with no CAD vs. subclinical CAD vs clinical CAD, respectively. The association with in-hospital mortality was independent of in-study outcome predictors (age, peripheral artery disease, active cancer, hemoglobin, C-reactive protein, LDH, aerated lung volume): subclinical CAD vs. No CAD: adjusted hazard ratio (adj-HR) 2.86 (95% confidence interval [CI] 1.14-7.17, p=0.025); clinical CAD vs. No CAD: adj-HR 3.74 (95% CI 1.21-11.60, p=0.022). Among patients with subclinical CAD, increasing CAC burden was associated with higher rates of in-hospital mortality (20.5% vs. 27.9% vs. 38.7% for patients with CAC score thresholds≤100, 101-400 and > 400, respectively, p < 0.001). The adj-HR per 50 points increase in CAC score 1.007 (95%CI 1.001-1.013, p=0.016). Cardiovascular risk factors were not independent predictors of in-hospital mortality when CAD presence and extent were taken into account.
CONCLUSIONS
The presence and extent of CAD are associated with in-hospital mortality and MI/CVA among hospitalized patients with COVID-19 disease and they appear to be a better prognostic gauge as compared to a clinical cardiovascular risk assessment.

Identifiants

pubmed: 33883086
pii: S0021-9150(21)00165-9
doi: 10.1016/j.atherosclerosis.2021.03.041
pmc: PMC8025539
pii:
doi:

Substances chimiques

Calcium SY7Q814VUP

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

136-143

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Références

JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Cardiovasc Res. 2020 Dec 1;116(14):2177-2184
pubmed: 32750108
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
Age Ageing. 2021 May 5;50(3):608-616
pubmed: 33951151
Eur Heart J Cardiovasc Imaging. 2020 Sep 1;21(9):1055-1056
pubmed: 32671381
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910
JACC Cardiovasc Imaging. 2020 Nov;13(11):2468-2470
pubmed: 33153535
Eur Heart J. 2018 Jul 1;39(25):2401-2408
pubmed: 29688297
Circulation. 2017 Nov 21;136(21):1993-2005
pubmed: 28847895
Coron Artery Dis. 2021 Aug 1;32(5):367-371
pubmed: 32732512
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Arch Gerontol Geriatr. 2021 Mar-Apr;93:104324
pubmed: 33352430
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Am Coll Cardiol. 2020 Sep 8;76(10):1168-1176
pubmed: 32679155
J Am Coll Cardiol. 2018 Jul 24;72(4):434-447
pubmed: 30025580
JACC Cardiovasc Imaging. 2020 Dec;13(12):2698
pubmed: 33303104
J Am Coll Cardiol. 2019 Sep 24;74(12):1608-1617
pubmed: 31537271
Eur Heart J Cardiovasc Imaging. 2020 May 1;21(5):479-488
pubmed: 32065624
Circ Cardiovasc Imaging. 2013 Jul;6(4):514-21
pubmed: 23756678

Auteurs

Alessandra Scoccia (A)

Azienda Ospedaliero-Universitaria di Ferrara, Cona, FE, Italy.

Guglielmo Gallone (G)

Division of Cardiology, Città Della Scienza e Della Salute, Dipartimento di Scienze Mediche University of Turin, Turin, Italy.

Alberto Cereda (A)

GVM Care & Research Maria Cecilia Hospital Cotignola, Italy.

Anna Palmisano (A)

IRCCS San Raffaele Scientific Institute, Italy.

Davide Vignale (D)

IRCCS San Raffaele Scientific Institute, Italy; Vita-Salute San Raffaele University, Italy.

Riccardo Leone (R)

IRCCS San Raffaele Scientific Institute, Italy; Vita-Salute San Raffaele University, Italy.

Valeria Nicoletti (V)

IRCCS San Raffaele Scientific Institute, Italy; Vita-Salute San Raffaele University, Italy.

Chiara Gnasso (C)

IRCCS San Raffaele Scientific Institute, Italy; Vita-Salute San Raffaele University, Italy.

Alberto Monello (A)

Guglielmo da Saliceto Hospital, Piacenza, Italy.

Arif Khokhar (A)

GVM Care & Research Maria Cecilia Hospital Cotignola, Italy.

Alessandro Sticchi (A)

GVM Care & Research Maria Cecilia Hospital Cotignola, Italy.

Andrea Biagi (A)

Guglielmo da Saliceto Hospital, Piacenza, Italy.

Carlo Tacchetti (C)

IRCCS San Raffaele Scientific Institute, Italy; Vita-Salute San Raffaele University, Italy.

Gianluca Campo (G)

Azienda Ospedaliero-Universitaria di Ferrara, Cona, FE, Italy.

Claudio Rapezzi (C)

GVM Care & Research Maria Cecilia Hospital Cotignola, Italy.

Francesco Ponticelli (F)

GVM Care & Research Maria Cecilia Hospital Cotignola, Italy.

Gian Battista Danzi (GB)

Ospedale di Cremona, Cremona, Italy.

Marco Loffi (M)

Ospedale di Cremona, Cremona, Italy.

Gianluca Pontone (G)

Centro Cardiologico Monzino IRCCS, Milano, Italy.

Daniele Andreini (D)

Centro Cardiologico Monzino IRCCS, Milano, Italy.

Gianni Casella (G)

Ospedale Maggiore, Bologna, Italy.

Gianmarco Iannopollo (G)

Ospedale Maggiore, Bologna, Italy.

Davide Ippolito (D)

San Gerardo Hospital, Monza, Italy.

Giacomo Bellani (G)

San Gerardo Hospital, Monza, Italy.

Gianluigi Patelli (G)

ASST Bolognini Hospital, Bergamo Est, Italy.

Francesca Besana (F)

ASST Bolognini Hospital, Bergamo Est, Italy.

Claudia Costa (C)

ASST Bolognini Hospital, Bergamo Est, Italy.

Luigi Vignali (L)

Parma University Hospital, Parma, Italy.

Giorgio Benatti (G)

Parma University Hospital, Parma, Italy.

Mario Iannaccone (M)

San Giovanni Bosco Hospital, ASL Città di Torino, Turin, Italy.

Paolo Giacomo Vaudano (PG)

San Giovanni Bosco Hospital, ASL Città di Torino, Turin, Italy.

Alberto Pacielli (A)

San Giovanni Bosco Hospital, ASL Città di Torino, Turin, Italy.

Caterina Chiara De Carlini (CC)

San L. Mandic Hospital, Merate, Italy.

Stefano Maggiolini (S)

San L. Mandic Hospital, Merate, Italy.

Pietro Andrea Bonaffini (PA)

ASST Papa Giovanni XXIII, Bergamo, Italy.

Michele Senni (M)

ASST Papa Giovanni XXIII, Bergamo, Italy.

Elisa Scarnecchia (E)

ASST Valtellina and Alto Lario, "Eugenio Morelli Hospital", Sondalo, Italy.

Fabio Anastasio (F)

ASST Valtellina and Alto Lario, "Eugenio Morelli Hospital", Sondalo, Italy.

Antonio Colombo (A)

GVM Care & Research Maria Cecilia Hospital Cotignola, Italy.

Roberto Ferrari (R)

GVM Care & Research Maria Cecilia Hospital Cotignola, Italy.

Antonio Esposito (A)

IRCCS San Raffaele Scientific Institute, Italy; Vita-Salute San Raffaele University, Italy.

Francesco Giannini (F)

GVM Care & Research Maria Cecilia Hospital Cotignola, Italy. Electronic address: giannini_fra@yahoo.it.

Marco Toselli (M)

GVM Care & Research Maria Cecilia Hospital Cotignola, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH